Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05406700 · ClinicalTrials.gov registry record · Early Phase 1
Niraparib In Recurrent IDH 1/2 Gliomas
A Early Phase 1 study of Low Grade Glioma and Glioma, Malignant, sponsored by Massachusetts General Hospital.
- Active
- Registry status
- Early Phase 1
- Development phase
- 16
- Enrollment target
- 1
- Study location
NCT05406700 is a Early Phase 1 study of Low Grade Glioma and Glioma, Malignant that is active but no longer recruiting, run by Massachusetts General Hospital. The registered enrollment target is 16 participants, below the 113-participant average among 23 other Low Grade Glioma trials with a reported enrollment target (86% lower). The trial reports 1 study location across 1 state.
The verdict
NCT05406700, a Early Phase 1 study of Low Grade Glioma and Glioma, Malignant, is active but no longer recruiting, sponsored by Massachusetts General Hospital.
- ACTIVE NOT RECRUITING
- Registry status
- Early Phase 1
- Development phase
- 16 participants
- Enrollment target
- 1
- Study location
Study Summary
This is a randomized, two-arm, open-label, phase 0 trial to assess intratumoral pharmacokinetics and pharmacodynamics of niraparib in subjects with progressive IDH1 or IDH2 mutant glioma. \- This research study involves an experimental treatment called Niraparib.
Conditions Studied
Interventions
- DRUG Niraparib
- DRUG Resection/Treatment with Niraparib
Study Locations (1)
Massachusetts
- Massachusetts General Hospital - Boston
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 16 participants |
| Start Date | 2023-05-18 |
| Est. Completion | 2026-10 |
| Phase | Early Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05406700
The ClinicalTrials.gov registry entry for NCT05406700 describes a study currently listed as active not recruiting, categorized as Early Phase 1. The registered enrollment target is 16 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 113-participant average among 23 other Low Grade Glioma trials with a reported enrollment target (86% lower). The listed sponsor is Massachusetts General Hospital, which has 2,032 total studies on file at ClinicalTrials.gov.
The record links to 5 conditions, with Low Grade Glioma appearing as the primary indexed condition, and to 2 interventions - of which Niraparib is the first listed.
NCT05406700 reports 1 study location spanning 1 distinct geographic area - top geographies include Massachusetts.
Frequently Asked Questions
What is clinical trial NCT05406700 about?
NCT05406700 is a clinical study titled "Niraparib In Recurrent IDH 1/2 Gliomas". This is a randomized, two-arm, open-label, phase 0 trial to assess intratumoral pharmacokinetics and pharmacodynamics of niraparib in subjects with progressive IDH1 or IDH2 mutant glioma. \- This research study involves an experimental treatment called Niraparib.
What is the current status of trial NCT05406700?
This trial is currently active not recruiting. It is a Early Phase 1 study. The enrollment target is 16 participants. The study started on 2023-05-18. Estimated completion is 2026-10.
What conditions does trial NCT05406700 study?
This clinical trial studies the following conditions: Low Grade Glioma, Glioma, Malignant, Recurrent Glioma, IDH1 Mutation, IDH2 Gene Mutation.
What interventions are being tested in trial NCT05406700?
The interventions under investigation include: Niraparib (DRUG), Resection/Treatment with Niraparib (DRUG).
Who is sponsoring clinical trial NCT05406700?
This trial is sponsored by Massachusetts General Hospital, which has 2,032 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05406700 being conducted?
This trial has 1 study location across Massachusetts. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Low Grade Glioma
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Evaluation of 18F-Fluciclovine Positron Emission Tomography - Magnetic Resonance Imaging (PET-MRI) in LGG
RECRUITING · Early Phase 1
-
A Vaccine Trial for Low Grade Gliomas
RECRUITING · Phase 2
-
A Study to Learn About the Study Medicine Called PF-07799544 as Monotherapy or in Combination in People With Advanced Solid Tumors
RECRUITING · Phase 1
-
MAPK Inhibition Combined With Anti-PD1 Therapy for BRAF-altered Pediatric Gliomas
RECRUITING · Phase 1
-
Post-Operative Dosing of Dexamethasone in Patients With Brain Tumors After a Craniotomy, PODS Trial
RECRUITING · Phase 2
-
A Study of the Drugs Selumetinib vs. Carboplatin and Vincristine in Patients With Low-Grade Glioma
RECRUITING · Phase 3
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.